Sign in →

Test Code ESTRCC Estradiol

Important Note

Many dietary supplements promoted for hair, skin, and nail benefits contain Biotin (Vitamin B7) levels up to 650 times the recommended daily intake.  High levels of Biotin can cause clinically significant incorrect lab test results, resulting in falsely high or falsely low results, depending on the test. Patients taking high doses of Biotin should be instructed to discontinue Biotin for at least 12 hours prior to lab testing.

Warning: Do not use specimens from patients taking Faslodex(R)

Reference Values

Healthy Men:          0-39.8  pg/ml

Healthy Women:

Follicular phase    19.5-144.2  pg/mL

Mid cycle phase    63.9-356.7 pg/mL

Luteal Phase         55.8-214.2  pg/mL

Postmenopausal    0-32.2 pg/mL

 

Healthy Pregnant Women:

1st trimester            154.0-3243.0  pg/mL

2nd trimester           1561.0-21280.0  pg/mL

3rd trimester            8525.0->30000.0  pg/mL

Day(s) Test Performed

Tuesday and Friday

Specimen Requirement

Serum

Draw blood in a gold-top (serum separator) gel tube. Label the specimen with the patient’s name (first and last), date of birth, date and time of draw, phlebotomist’s initials, and as serum. Spin down and send 1 mL of serum refrigerated. 

 

Specimen stability:

20 hours at room temperature when spun

2 days at 2-8°C

≤ -20°C for longer storage

Minimum volume:    0.5 mL
 

Specimen rejection criteria:  High doses of biotin will affect this assay

CPT Codes

82670

Method

Electrochemiluminesence immunoassay

Useful For

All applications that require moderately sensitive measurement of estradiol:

  • Evaluation of hypogonadism and oligo-amenorrhea in females
  • Assessing ovarian status, including follicle development, for assisted reproduction protocols
  • In conjunction with lutenizing hormone measurements, monitoring of estrogen replacement therapy in hypogonadal premenopausal women
  • Evaluation of feminization, including gynecomastia, in males
  • Diagnosis of estrogen-producing neoplasms in males, and to a lesser degree, females
  • As part of the diagnosis and work-up of precocious and delayed puberty in females, and to a lesser degree, males
  • As part of the diagnosis and work-up of suspected disorders of sex steroid metabolism, eg, aromatase deficiency and 17 alpha-hydroxylase deficiency
  • As an adjunct to clinical assessment, imaging studies and bone mineral density measurement in the fracture risk assessment of postmenopausal women, and to a lesser degree, men
  • Monitoring low-dose female hormone replacement therapy in post-menopausal women
  • Monitoring antiestrogen therapy (eg, aromatase inhibitor therapy)